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Purpose of the review: 
Migraine is a common, highly disabling disorder. Its treatment involves acute and preventive therapy. 
Many of available preventive medications are not well tolerated, which results in poor compliance 
and limited effectiveness. Cannabinoids have been proposed for the treatment of migraine but their 
efficacy and tolerability are controversial. 
Recent findings: Cannabinoids modulate functions and activity of signaling pathways that have a key 
role in pain control. Growing preclinical evidence and initial clinical findings suggest that modulation 
of the endocannabinoid system, via endogenous or exogenous cannabinoids may be relevant for 
migraine via multiple mechanisms.  
Summary: The endocannabinoid system qualifies as an interesting area of research worth exploration 
in the quest for therapeutic targets for the treatment of migraine.  
 
 







Our knowledge of the endocannabinoid system (ES) largely originated from studies aimed at 
identifying the mechanism of action and the properties the plant Cannabis sativa, better known as 
marijuana. The identification of its main active psychoactive ingredients led to the discovery of the 
cannabinoid receptors and their endogenous agonists, the endocannabinoids (ECs).  
In recent years, much attention has been drawn to the use cannabinoids in several areas of 




C. sativa L, an annual wind-pollinated dioecious (male and female reproductive organs in 
separate plants) herb, is one of the world’s oldest cultivated plants. L is an abbreviation for Linnaeus 
who invented the botanical classification scheme [1]. C. sativa L is usually called “hemp” when used 
as a source of fiber, “hempseed” when used as a source of seed oil, and “marijuana” (sometimes 
spelled “marihuana”) when used as a drug for therapeutic or recreational purposes. Previously it was 
believed that there were at least two species; C. sativa L (narrow leaves, branches apart, light green, 
and tall with few flowers) and Cannabis indica L (wide broad leaves, branches close together, deep 
green, and short and bushy with dense flowers). Cannabis ruderalis L (varied leaflets and short 
stature) is sometimes considered a third species.  
Many now believe that there is just one species of C. sativa L with subgroups called cultivars. 
These are selected for a characteristic or combination of characteristics, are distinct, uniform, and 
stable in these characteristics, and when propagated by appropriate means, retains those 
characteristics [2,3]. 
C. sativa L is the species and sativa, indica, and ruderalis are subspecies. Pisupati and 
colleagues [4] analyzed the nuclear genomic diversity among cannabis varieties, including fiber hemp 
and seed oil hemp, high cannabinoid drug-types, and feral populations. They found the existence of 
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at least three major groups of diversity with European hemp varieties, with genetic groups having 
different cannabinoid and terpenoid content. 
It took more than 100 years to identify the chemical components in cannabis flowers. Over 
104 different phytocannabinoids (plant cannabinoids) have been identified including D9-
tetrahydrocannabinol (THC) and cannabidiol (CBD). Other compounds include terpenes, flavonoids, 
steroids, noncannabinoid phenols, vitamins, and pigments. These have independent beneficial effects 
which must be considered when being used therapeutically. CBD and THC are both present in the 
plant as their carboxylic precursors (D9-tetrahydrocannabinolic acid [THCA] and cannabidiolic 
acid). They are produced after the heating or drying of the flowers. THCA is synthesized within the 
glandular trichomes present in the flowers, leaves, and bracts (modified or specialized leaf, associated 
with a reproductive structure such as a flower) of the female plant. Terpenes are volatile compounds 
responsible for the typical smell and taste of cannabis. More than 120 different types of terpenes have 
been identified in cannabis. Terpenes have a wide range of known biological effects. Prior, cannabis 
classification systems did not take the terpenes into account [5,6]. 
Today’s cannabis plants are hybrid descendants of two genetically divergent gene pools – 
narrow leaf drug (NLD) and broad-leaflet drug (BLD). The original NLD plants had a relatively high 
THC and low CBD content. BLD later introduced from Afghanistan were short bushy plants with 
broad, dark green leaflets. BLD plants could produce phytocannabinoids varying from all THC to all 
CBD. In the late 1970s, growers began to call the original NLD varieties ‘sativas’ because they 
resembled narrow leaf hemp fiber varieties. The Afghan BLD hashish varieties were called “indicas.”  
But both NLD and BLD populations belong to different subspecies of C. indica, subspecies indica 
(NLD) and subspecies afghanica (BLD) [7,8].  
There is a large disparity between patients, growers, and scientists to describe this plant.  
Scientists often use the term sativa for low THC content plants and the term “indica” for plants with 
high THC content. In the “cultural” language “sativa” refers to plants with very high THC content 
and low or no CBD content whereas indica refers to plants with moderate THC and CBD content. It 
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is important to recognize that popular literature about marijuana strains uses the terms indica and 
sativa in a way that is distinct from the scientific usage and both are inaccurate since form does not 
determine chemistry[3]. 
Classifications now take into account the chemical content (chemotype/chemovars) of C. 
sativa L. Cannabis plants typically exhibit one of the three different chemotypes based on the absolute 
and relative concentrations of THCA and cannabidiolic acid. Type I refers to high THC chemovars, 
Type II refers to mixed THC/CBD chemovars, and Type III refers to CBD-predominant chemovars. 
With modern analytical techniques, rapid and comprehensive analysis of all cannabinoids and 
terpenes present in cannabis products can be done. This allows an expanded cannabis classification 
scheme that considers the primary cannabinoid (THC or CBD) and their concentration, terpenoid 
content and concentration, plant shape, scent, taste, and use. 
From cannabis to endocannabinoids 
The search for the site of action of THC led to the discovery of 2 G protein-coupled receptors 
for THC, named cannabinoid receptor type-1 (CB1) and type-2 (CB2) and the endogenous 
cannabinoids. endocannabinoids are endogenous lipids that engage cannabinoid receptors. The best-
characterized endocannabinoids are arachidonoyl ethanolamide, best known as anandamide (AEA) 
and 2-arachidonoyl glycerol (2-AG). AEA is metabolized mostly by fatty acid amide hydrolase 
(FAAH), whereas 2-AG by monoglyceride lipase (MAGL) [9]. Precursors of AEA and 2-AG are 
present in lipid membranes, where they are transformed on demand into the final product and then 
released into the extracellular space. 
Accumulated evidence suggests the existence of additional targets for endocannabinoids in 
addition to CB1 and CB2. This seems the case for the purported ‘CB3’ receptor GPR55 and the 
transient receptor potential vanilloid 1 (TRPV1) ion channel. Other potential endocannabinoid 
targets, such as peroxisome proliferator-activated receptor a and g are localized in the nucleus, where 
they shuttle from/to the cytosol in a ligand-dependent manner.  
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CB receptors, endogenous ligands that activate them, and the enzymes responsible for the 
synthesis and degradation of the endocannabinoids constitute altogether the endocannabinoid system. 
AEA is responsible for maintaining basal endocannabinoid tone and has a high selectivity 
for the CB1 receptor over the peripheral CB2 receptor [9]. AEA also binds to the TRPV1, an 
ionotropic receptor that is responsible for the integration of noxious stimuli that cause pain [10]. In 
contrast to AEA, 2-AG is a full agonist for both CB1 and CB2 [9]. CB1 receptors are found in 
neuroanatomical regions involved in pain processing and modulate the release of several 
neurotransmitters [11]. They are also expressed in afferent fibers and in many nonneural cells. CB1 
receptors are involved in pain transmission and modulation at multiple levels of the neuroaxis from 
periphery to central nervous system [9,12]. CB2 receptors are located primarily in immune cells, 
even though CB2 mRNA was detected within the spinal cord and CB2 protein in the brain [13]. CB 
receptors co-localize with opioid receptors and augment the analgesic effects of opioids, probably 
via pharmacodynamics mechanisms. GPR55 is located in the brain, in the peripheral nervous 
system and in mast cells [14]. The enzymes involved in the synthesis of AEA and 2-AG are the N-
acylphosphatidylethanolaminephospholipase D and the sn-1-specific diacylglycerol lipase, 
respectively [9]. Once synthesized and released, endocannabinoids are removed from the 
extracellular space through an endocannabinoid membrane transporter (EMT) and subsequently 
hydrolyzed. AEA is mostly hydrolyzed by FAAH, which releases, arachidonic acid and 
ethanolamine or arachidonic acid and glycerol, whereas 2-AG degradation is mainly because of a 
cytosolic MAGL [9]. 
The theoretical bases for a role of the endocannabinoid system in migraine pain: Cannabinoids 
and Endocannabinoids 
THC, the constituent responsible for the mind-altering and intoxicating effects of C. Sativa, acts on 
CB1 and CB2 receptors. CBD binds to other receptors, and is devoid of the psychoactive effects 
associated with THC. CBD is the most abundant cannabis-derived non-CB1/CB2 receptor ligand, that 
may exert some effects via inhibition of FAAH [15,16]. In addition to its psychotropic properties, 
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cannabis has long been known to have analgesic, immunomodulatory, and anti-inflammatory effects 
[17]. CBD reduces inflammatory and neuropathic pain by modulation of 5-HT1A (serotonin 1A) 
receptors and TRPV1 channels [18&]. Similarly, to some other cannabinoids, CBD suppresses 
cytokines and chemokines release, decreases production of reactive oxygen species and modulates 
immune cell system [19] (Table 1). 
 Experimental studies show that THC is effective in reducing multiple types of pain including 
pain caused by acute noxious stimuli and chronic inflammation [43]. THC prevents depression of home 
cage wheel running caused by migraine-like pain after dural TRPA1 agonist microinjection, in a time- 
and dose-dependent manner [44,45]. Moreover, THC and other CB1 agonists dose-dependently reduce 
cortical spreading depression amplitude, duration, and propagation velocity in a rat model [26]. WIN 
55,212-2, a potent CB1 agonist, inhibits trigeminocervical complex A and C-fiber afferent activity 
[46]. 
Theoretically, the endocannabinoid system may target migraine in multiple pathways 
(glutamatergic, serotoninergic, opiatergic and inflammatory) [47–49] and at multiple anatomic levels. 
In the periphery, endocannabinoids may affect neurogenic inflammation mediated by the 
trigeminovascular system in the meninges via their stabilizing effect on mast cells [14,50] and the 
inhibition of calcitonin gene-related peptide (CGRP)-induced dilatation of dural blood vessels and 
neuronal pronociceptive activity [51]. Centrally, activation of CB1 receptors in the ventrolateral 
periaqueductal gray (PAG) modulates nociceptive trigeminovascular transmission in the 
trigeminocervical complex via a mechanism mediated by 5HT1B/1D receptors [52]. 
Endocannabinoid system also affects the descending pathways of pain control by acting at either CB1 
or TRPV1 receptors [53,54]. Consistently, microinjections within the PAG and rostral ventrolateral 
medulla of URB597 (cyclohexylcarbamic acid 3’-carbamoylbiphenyl-3-yl ester), a global FAAH 
inhibitor, enhance analgesia via TRPV1 and CB1 receptors in animal models of neuropathic pain 
[53]. Again, the levels of AEA and 2-AG are significantly increased in animal models of neuropathic 
pain, to suggest a compensatory upregulation of endocannabinoids directed at the inhibition of pain 
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in pathological conditions [55]. AEA acts presynaptically to prevent release of nitric oxide by CGRP 
in the dura mater [51]. Also, artificially increased levels of 2-AG and AEA in the dorsal PAG enhance 
stress induced analgesia [56]. 
Studies conductedonthemigraine-specific animal model based on nitroglycerin (NTG) 
administration showed increased FAAH activity and up-regulation of CB1 receptor binding sites in 
the rat hypothalamus and in the medulla [57]. In NTG-treated rats, activity of FAAH and MAGL 
hydrolases increased in the mesencephalon, a key area in migraine pathophysiology [57], to suggest 
a decrease in the endocannabinoid tone. Consistently, we observed that AEA administration 
significantly reduced NTG-induced nocifensive behavioural and neuronal activation in the nucleus 
trigeminal caudalis (NTC), another key area for migraine [58], and others reported reduced central 
sensitization through TRPV1, cyclooxygenase-2 expression, and nuclear factor kappa B inhibition in 
NTC [59]. If AEA and CB1-mediated mechanisms are important, we must not overlook the possible 
role of CB2-mediated mechanisms when considering that the activation of these receptors 
significantly decreases nocifensive behaviour in rats previously made hyperalgesic by NTG [60]. 
Modulation of CB2 receptor activity seems particularly appealing, as they induce analgesic effects 
without producing tolerance or central side-effects [61,62]. 
 FAAH inhibition causes analgesia and reduces inflammation in animal models of migraine 
pain [63,64]. NTG-induced mechanical allodynia and c-Fos protein in the NTC are both suppressed in 
FAAH deficient mice or after URB597 treatment, thus strongly indicating a role for AEA in migraine 
pain [64]. In agreement, URB937, a peripherally restricted FAAH inhibitor, reduces NTG-induced 
nocifensive behavior, and c-Fos expression in the NTC and locus coeruleus [63], thus underscoring the 
role of peripheral mechanisms, possibly related to the anti-inflammatory activity of endocannabinoids 
[65&&]. Indeed, URB937 acts only peripherally, maintaining higher levels of AEA released by 
nervous terminal located in the injured peripheral tissues or in the dura, via CB1 receptor activation in 
trigeminovascular endings [66]. It is worth noting that similar effects have been reported with biphenyl-
3-ylcarbamic acid cyclohexyl ester (URB602), a reversible MAGL inhibitor that significantly 
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decreases NTG induced neuronal activation in PAG and NTC, to suggest once more that modulation 
of CB2 may also play a role in migraine [67&&]. These findings support the hypothesis that 
modulation of the endocannabinoid system may be an extremely valuable approach for the treatment 
of migraine-related pain and hyperalgesia [68]. However, controversy exists as regards the safety of 
the modulation of the endocannabinoid system, in particular as regards the inhibition of 
endocannabinoids catabolism when off-target effect is not properly ruled out [69]. Technological 
advances allow a full characterization of protein interaction landscape and warrants further 
investigation along this promising pathway. 
Clinical data 
Clinical evidence in favor of the need to further investigate the role of the endocannabinoid system 
in migraine is more scattered, but nonetheless compelling. Women with migraine without aura bear 
increased activities of FAAH and EMT, to suggest reduced AEA levels [70]. In another study based 
on PET detection of CB1 receptors, women with episodic migraine showed increased binding in pain-
modulating areas of the brain [71]. Variants in the CB1 receptor gene increase the risk of migraine 
attack with nausea in life stress exposed patients [72&]. A more recent study failed to detect 
significant changes in the plasma levels of AEA and other fatty acid ethanolamides in episodic 
migraineurs [73], probably as a consequence of a high interpatient variability in the evaluated cohorts. 
A more consistent alteration of endocannabinoid system seems to be implicated in chronic 
migraine. FAAH and EMT levels were lower in the platelets of patients with chronic migraine when 
compared to either controls or episodic migraine [74]. Furthermore, FAAH levels decreased in 
patients with chronic migraine and acute medication overuse after detoxification, in parallel with the 
clinical improvement and with the restored pain control, to suggest that the catabolizing pathway is 
altered in these patients [75]. Increased levels of N-palmitoylethanolamine (PEA), a fatty acid amide 
belonging to the endocannabinoid system, were found in the cerebrospinal fluid of chronic migraine 
patients [76], a finding interpreted by the authors as a compensatory mechanism. 
Cannabinoids in the management of migraine: Clinical effects and Tolerability 
 10 
 PEA has showed properties that may be useful in pain conditions [77,78]. Limited evidence 
suggests the possible efficacy of ultramicronized PEA in reducing the number of migraine 
attacks/month, regardless of age or sex, and the use of acute medications [79,80]. 
 Cannabis-based medicines are approved only for a few indications. None are approved for 
pain or headache. The Health Effects of Cannabis and Cannabinoid report [81] concluded that there is 
substantial evidence that cannabinoids are effective for the treatment chronic pain in adults. But little 
is known about the efficacy, dose, routes of administration, or side effects of available cannabis. 
Anecdotal evidence suggests a role for cannabis in the treatment of headache and migraine [82,83], but 
no controlled clinical studies have been done. Anecdotal benefit has been reported in pseudotumor 
cerebri [84] and refractory cluster headaches [85]. Cannabis use is very frequent in French cluster 
headache patients; most had variable, uncertain, or even negative effects of cannabis smoking [86]. 
Headache is an adverse event associated with cannabinoid medications, and is very common with 
cannabis withdrawal [87]. It is therefore possible that using cannabis simply relieves headache caused 
by cannabis withdrawal.  
Rhyne et al. [88] did a retrospective chart review of 121 adults with migraine headache 
referred for treatment with medical marijuana and had at least one follow-up visit. Migraine headache 
frequency decreased from 10.4 to 4.6 headaches per month (P<0.0001) and self-reported positive 
effects were recorded in 48 patients (39.7%). The scientific validity of this study is however limited 
by multiple issues: high rate of drop-outs, inconsistent chart documentation, and so on. 
Nabilone is a synthetic cannabinoid with a highly selective agonistic activity for CB1 and 
CB2 receptors. It decreased analgesic intake and improved pain in a small double-blind, placebo-
controlled trial of 26 patients with treatment refractory medication overuse headache, a frequent 
complication of chronic migraine [89]. They were given nabilone (0.5mg) or ibuprofen (400 mg) for 
8 weeks, then after a week-long washout period, switched to the other drug for a second 8-week 
course. Nabilone was significantly more effective than ibuprofen in reducing pain intensity, analgesic 
intake, as well as in improving quality of life. Patients only had mild adverse effects. A different 
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multicenter, double-blind, placebo-controlled study of the safety and efficacy of a dronabinol, a 
synthetic form of THC, delivered with a metered dose inhaler for the treatment of migraine 
(clincaltrials.gov, The national clinical trial (NCT) Identifier: NCT00123201) has been completed for 
several years, without publication of results from the sponsor Solvay Pharmaceuticals, Brussels, 
Belgium. 
Tolerability is a concern in the use of cannabinoids. Dosing is individualized and requires 
titration. Those with no prior experience should start with a very low dose and stop if undesirable 
side-effects occur. Psychoactive effects occur at doses above the individual consumer’s psychotropic 
threshold. They are generally pleasurable and relaxing. However, this can turn into dysphoria, 
anxiety, or even panic. Impairment of memory, reductions in psychomotor and cognitive 
performance, and disordered perception of the passage of time can occur. Common physical effects 
are tiredness, dizziness, tachycardia, orthostatic hypotension, dry mouth, reduced lacrimation, muscle 
relaxation, and increased appetite. Tolerance develops too many of these undesired effects of 
cannabinoids particularly tiredness, dizziness, and cardiovascular and psychoactive effects over a 
period of days or weeks [90]. 
There is an association between cannabis use and the development of psychosis, at least in 
vulnerable subjects [91], with the highest risk among the most frequent users. The evidence is unclear 
as to whether and how cannabis use is associated with heart attack, stroke, and diabetes, but 
tachycardia often occurs with acute dosage; tolerance developing with chronic exposure. Cannabis 
use increases the risk of being involved in a motor vehicle accident. Smoking cannabis during 
pregnancy is linked to lower birth weight in the offspring. The relationship between smoking cannabis 
during pregnancy and other pregnancy and childhood outcomes is unclear. The hyperemesis 
syndrome can occur in chronic daily cannabis users. It is characterized by severe, intractable episodes 
of nausea and cyclic vomiting accompanied by abdominal pain (typically epigastric or periumbilical); 
relieved by compulsive hot water bathing or showering [92]. Treatment includes: cessation of 
cannabis use, rehydration, and psychological counseling. 
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Conclusions  
C. sativa is one of the world’s oldest cultivated plants. It has been used for thousands of years. Many 
believe it is effective for migraine and headache, but controlled clinical trials are missing. Anecdotal 
information does not provide THC and CBD content or the amount and type of terpenes. Cannabis is 
effective for pain, we still need to know if it is effective for headache. 
The modulation of the endocannabinoid system, in particular in the processing of nociceptive 
signals in the trigeminovascular system, may prove a well-tolerated and pharmacologically sound 
therapeutic option for migraine [93]. Additional studies are needed to explore the neurobiological 
mechanisms and neural circuits involved. 
KEY POINTS 
1) Alterations in the Endocannabinoid System seem to be implicated in migraine pathogenesis and 
progression 
2) Exogenous and endogenous cannabinoids may have therapeutic benefits in migraine, provided that 
tolerability issues are addressed  
3) More research is necessary for the complete characterization of the multiple components of 
Cannabis and for the identification of safe modulators of the endogenous cannabinoid system as 
suitable targets for migraine treatment. 
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